Want to join the conversation?
In 2Q16, net sales for $MNK's Acthar were up nearly 9% driven primarily by steady volume growth. INOMAX net sales were up 14% on a pro forma basis. The Therakos platform had net sales growth of 13% on a pro forma basis, on a constant currency basis. In the surgical space, $MNK achieved 4% revenue growth for OFIRMEV.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.